What immediate actions should be taken for a patient who accidentally ingested 75 mg of apixaban (Eliquis)?

Management of Accidental 75 mg Apixaban (Eliquis) Ingestion

If a patient accidentally took 75 mg of apixaban (15 times the standard 5 mg dose), immediately assess for active bleeding, consider activated charcoal if within 2-4 hours of ingestion, monitor closely for 24-48 hours, and avoid reversal agents unless life-threatening bleeding occurs.

Immediate Assessment and Risk Stratification

The 75 mg dose represents a significant overdose (7.5 times the typical daily dose of 10 mg). However, evidence from multiple overdose cases demonstrates that clinically significant bleeding is uncommon even with massive overdoses 1, 2, 3, 4, 5.

Initial Actions:

• Assess for active bleeding: Check for signs of hemorrhage (GI bleeding, hematuria, intracranial bleeding, ecchymoses)
• Obtain baseline labs: CBC, PT/INR, aPTT, creatinine, anti-Xa activity if available (though not necessary for management decisions)
• Neurological examination: Assess for any signs of intracranial bleeding

Decontamination Strategy

Activated charcoal should be administered if the patient presents within 2-4 hours of ingestion 6, 7. This recommendation is supported by:

• Apixaban's peak concentration (Cmax) can be delayed up to 17 hours post-massive ingestion 3
• Activated charcoal reduces apixaban absorption and lowers plasma concentration 7
• Case reports suggest activated charcoal may be effective even beyond the typical 1-2 hour window in overdose scenarios 2, 3

Dosing: Standard activated charcoal 50 grams orally (or 1 g/kg in children) if no contraindications exist (altered mental status without airway protection, bowel obstruction, perforation).

Monitoring Protocol

Duration and Frequency:

• Monitor for at least 24 hours (approximately 2 half-lives of apixaban) 7
• In massive overdoses, consider extending monitoring to 48 hours given potential for delayed peak concentrations
• Serial vital signs every 2-4 hours
• Repeat hemoglobin/hematocrit at 6-12 hours if initial values normal

Expected Pharmacokinetics:

Apixaban demonstrates first-order elimination kinetics even at supratherapeutic levels 1, 3, 4:

• Half-life: 6-15 hours (normal renal function) 6
• Peak levels may occur 2-17 hours post-ingestion in overdose 3
• Therapeutic range typically returns within 10-24 hours 4

Reversal Agent Considerations

Do NOT routinely administer reversal agents for asymptomatic overdose 6, 7. Reserve reversal for:

Indications for Andexanet Alfa:

• Life-threatening bleeding only (intracranial hemorrhage, massive GI bleeding with hemodynamic instability, uncontrolled bleeding requiring transfusion) 8, 6
• High-dose andexanet: 800 mg IV bolus at 30 mg/min, followed by 8 mg/min infusion for up to 120 minutes 6

Alternative Hemostatic Agents (if andexanet unavailable):

• Four-factor prothrombin complex concentrate (4F-PCC) 8, 6
• Activated PCC (aPCC) as second-line 6

Important caveat: Routine coagulation tests (PT, INR, aPTT) and anti-Xa levels do not reliably guide reversal decisions and should not delay treatment if life-threatening bleeding is present 7.

What NOT to Do

• Do not use protamine sulfate or vitamin K - they are ineffective for apixaban reversal 7
• Do not perform hemodialysis - it does not substantially affect apixaban exposure 7
• Do not administer prophylactic reversal agents - case series show excellent outcomes without intervention 1, 2, 3, 4, 5

Evidence from Overdose Cases

Multiple case reports provide reassuring data:

• 300 mg ingestion (60 tablets): No bleeding despite peak level of 3654 μg/L 3
• 250 mg ingestion: Massive bleeding occurred but was multifactorial (polysubstance overdose) 1
• 200 mg ingestion: Only minor bleeding at line insertion site 4
• Pediatric exposures <6 years: No clinically significant bleeding in 744 cases 5

Disposition

• Admit for observation if symptomatic, high-risk features (elderly, renal impairment, concurrent antiplatelet use), or presents >2-4 hours post-ingestion (missed charcoal window)
• Discharge after 24 hours if asymptomatic with normal labs and no bleeding
• Provide strict return precautions for any signs of bleeding
• Ensure patient understands proper dosing before discharge

Key Pitfalls to Avoid

1. Over-treating asymptomatic patients: The wide therapeutic index of apixaban means most overdoses are well-tolerated
2. Delaying activated charcoal: Consider it even if presentation is delayed beyond typical 1-2 hour window
3. Premature discharge: The delayed peak concentration in overdose necessitates extended observation
4. Using reversal agents prophylactically: This increases thrombotic risk without proven benefit in asymptomatic patients 8